Watchlist Price Alert

Humacyte Inc. (HUMA)

NASDAQ: HUMA · Real-Time Price · USD

1.72

0.40 (30.30%)

At close: May 13, 2025, 3:34 PM

30.30% (1D)

Bid	1.71
Market Cap	266.71M
Revenue (ttm)	7.23M
Net Income (ttm)	-148.7M
EPS (ttm)	-1.26
PE Ratio (ttm)	-1.36
Forward PE	-6.67
Analyst	Buy

Ask	1.72
Volume	13,546,343
Avg. Volume (20D)	3,731,175
Open	1.56
Previous Close	1.32
Day's Range	1.47 - 1.80
52-Week Range	1.15 - 9.97
Beta	1.64

About HUMA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol HUMA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for HUMA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

New

Humacyte has released their quartely earnings on May 13, 2025:

Revenue of $517K misses estimates by $13K, with Infinity% YoY growth.

EPS of -0.1 exceeds estimates by 0.09, with 65.52% YoY growth.

Next Earnings Release

Humacyte Inc. is scheduled to release its earnings on May 13, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 minutes ago New

Humacyte shares are trading higher after the compa... Unlock content with Pro Subscription

1 month ago

-30.56%

Humacyte shares are trading lower after the company priced a $50 million public offering of 25 million common shares at $2.00 per share.

News

5 hours ago · seekingalpha.com

Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript

Humacyte, Inc. (NASDAQ:HUMA ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Thomas Johnson - Director-Corporate Communications, LifeSci Advisors, IR Laura Niklason - Fo...

Just now · zacks.com

Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates

Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.29 per share a year ago.

1 week ago · zacks.com

Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know

The latest trading day saw Humacyte, Inc. (HUMA) settling at $1.45, representing a +1.4% change from its previous close.

1 week ago · zacks.com

All You Need to Know About Humacyte, Inc. (HUMA) Rating Upgrade to Buy

Humacyte, Inc. (HUMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 weeks ago · zacks.com

Humacyte, Inc. (HUMA) Ascends But Remains Behind Market: Some Facts to Note

Humacyte, Inc. (HUMA) reachead $1.48 at the closing of the latest trading day, reflecting a +0.68% change compared to its last close.

3 weeks ago · zacks.com

Humacyte, Inc. (HUMA) Increases Despite Market Slip: Here's What You Need to Know

Humacyte, Inc. (HUMA) reachead $1.55 at the closing of the latest trading day, reflecting a +0.65% change compared to its last close.

1 month ago · seekingalpha.com

Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript

Humacyte, Inc. (NASDAQ:HUMA ) Q4 2024 Earnings Conference Call March 27, 2025 8:30 AM ET Company Participants Thomas Johnson - Director, Corporate Communications, LifeSci Advisors, IR Laura Niklason -...

1 month ago · zacks.com

Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy...

1 month ago · zacks.com

Humacyte, Inc. (HUMA) Flat As Market Gains: What You Should Know

In the closing of the recent trading day, Humacyte, Inc. (HUMA) stood at $3.32, denoting no change from the preceding trading day.

2 months ago · zacks.com

Wall Street Bulls Look Optimistic About Humacyte, Inc. (HUMA): Should You Buy?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe...

Load More News